Business
IDEXX develops veterinary diagnostic instruments, tests, software and water-testing products.
IDEXX converted veterinary-diagnostics demand into double-digit growth, a 32% margin and more than $1 billion of free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 10.4%OK
- Profitability — Net income grew 19.3% to $1.059B from $887.867MOK
- Cash flow — Free cash flow grew 30.8% to $1.057B from $808.079MOK
- Margins — Operating margin expanded 265 bps to 31.60%OK
- Accounting — Exceptional recurring diagnostics economicsNote
- Insiders — 0 purchases and 14 salesWatch
Where the revenue comes from
Fiscal 2025, as IDEXX LABORATORIES INC /DE reports it. History and quarterly detail are in the app.
- CAG Diagnostics recurring revenue:$3.4B
- Product revenue$2.5B
- Service revenue$1.8B
- Veterinary software, services, and diagnostic imaging systems:$345.9M
- CAG Diagnostics capital - instruments$200.2M
Leadership changes
From IDEXX LABORATORIES INC /DE's own filings, the day they're filed.
- Karen Peacock · Director · appointmenteff. 2025-10-06
- Andrew Emerson · President · appointmenteff. 2025-01-01
- Jonathan W. Ayers · member · departureeff. 2024-11-08
Latest filings
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-05-15
- 8-K · Company announcement2026-05-05
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about IDEXX LABORATORIES INC /DE, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.